DGX
Heads-up: USD ADP Nonfarm Employment Change is due in 13 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD ISM Non-Manufacturing Prices Paid is due in 15 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD ISM Non-Manufacturing PMI is due in 15 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD EIA Crude Oil Stocks Change is due in 15 h (high impact). The outlook can shift noticeably around it.
- Quest Diagnostics posted a strong Q3 with revenue up 10% year over year and adjusted diluted EPS up 15.4%, prompting raised full-year 2026 guidance.
- The bullish case is purely fundamental — no technical signals are active, so chart confirmation is absent and price trends provide no independent backup.
- A dense US macro window lands within two days — Fed decision, FOMC statement and presser, PCE inflation and GDP — adding backdrop event risk for US healthcare names.
- The main threat to the bulls is sustaining organic momentum while healthcare spending faces possible macroeconomic pressure if consumer confidence slips.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
The case for Quest Diagnostics rests entirely on the fundamental picture, since no technical signals are active in this analysis. The most recent news item, now five days old, flags a strong third-quarter print with revenue up 10% year over year and adjusted diluted EPS up 15.4%, alongside an upward revision of full-year 2026 revenue and earnings guidance.
Read full analysis
That is a confident management signal, and the growth is described as organic rather than acquisition-driven, which usually carries more durability. Short-, mid- and long-term horizons are all marked bullish, and with the technical side silent, the stance is driven by fundamentals alone. The tension worth noting is timing risk. The bullish case leans on sustaining organic momentum, while the near-term US calendar is dense: durable goods orders and consumer confidence arrive within roughly a day, followed shortly by the Fed rate decision, the FOMC statement and press conference, then PCE inflation and GDP within two days. None of these releases carries a designated direction for this asset, so they act as macro backdrop — but a hawkish Fed night or an inflation print that runs hotter than expected could tighten financial conditions and dampen risk appetite across US equities, including diagnostics. Also watch healthcare spending if the consumer confidence reading stays soft. In short, a strongly bullish fundamental setup, unconfirmed by technicals, facing a catalyst-heavy macro week where the near-term tone may be set by the macro mood rather than the company's own numbers.
Supporting factors
- Q3 revenue up 10% year over year to $3.10B reflects durable organic growth.
- Adjusted diluted EPS rose 15.4% to $3.00, a strong profitability read.
- Full-year 2026 revenue and EPS guidance raised, signaling management confidence.
- High news impact score of 7 with a bullish sentiment reading supports the fundamental case.
Risks and what to watch
- Failure to sustain organic growth momentum, explicitly flagged in the source analysis.
- Macroeconomic pressure on healthcare spending, also named in the source analysis.
- Dense macro week — Fed decision, FOMC statement and presser, PCE, GDP — acts as event risk with no fixed direction for DGX.
- No technical signals are present, so the bullish view lacks price-action confirmation.
- The supporting news is already five days old, so its catalyst effect may be fading.
Why is Quest Diagnostics considered strongly bullish right now?
The bullish classification comes from the fundamental reading. The most recent company coverage reported third-quarter revenue of $3.10B, up 10% year over year, and adjusted diluted EPS up 15.4% to $3.00, with growth described as organic. Management also raised full-year 2026 revenue and earnings guidance, pointing to confidence in the operational trajectory. However, no technical signals are currently active, so the bullish stance is entirely fundamental and lacks independent confirmation from chart behavior.
Does the Federal Reserve's interest rate decision directly drive DGX?
Not in a fixed or direct way. In this analysis, US releases set the macro backdrop for a dollar-based company and do not carry a designated direction for the asset. The upcoming Fed decision, FOMC statement and press conference, alongside PCE inflation and GDP data, can shape risk appetite across US equities broadly, but they should not be read as a specific catalyst for Quest Diagnostics. A hawkish surprise could tighten financial conditions and pressure valuations generally, while a dovish one might support risk sentiment.
What could invalidate the bullish outlook for Quest Diagnostics?
The main risks are a failure to sustain the organic growth momentum behind the Q3 beat and macroeconomic pressure on healthcare spending, both named in the source analysis. On top of that, the dense US macro calendar — the Fed decision, FOMC messaging, PCE inflation and GDP, all within two days — adds event risk that could shift equity risk appetite without any direct link to DGX fundamentals. Finally, since technical signals are absent, a meaningful price decline would have no chart-based counterweight to argue against it.
Should DGX holders expect near-term volatility this week?
There is reason to anticipate a reactive market environment. Multiple high-impact US releases arrive within roughly two days: durable goods orders and consumer confidence first, then the Fed rate decision with the FOMC statement and press conference, followed by core PCE inflation and GDP. None of these carries a fixed direction for Quest Diagnostics, but they can move the macro mood that colors all US equities, including healthcare names. Beyond that, the underlying bullish fundamental case is not backed by any active technical signal.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
Economic data for DGX
Full calendarRecently released
- TodayUSDJOLTS Job Openings●●●Forecast 6.779MPrevious 7.079M
- November 2, 2026USDISM Manufacturing PMI●●●Forecast 54.7Previous 54.5
- November 2, 2026USDISM Manufacturing Prices Paid●●●Forecast 80.7Previous 77.9
Coming up
- TomorrowUSDADP Nonfarm Employment Change●●●Forecast 64KPrevious 90Kin 13h
- TomorrowUSDISM Non-Manufacturing Prices Paid●●●Forecast 69.5Previous 74.0in 15h
- TomorrowUSDISM Non-Manufacturing PMI●●●Forecast 55.2Previous 54.9in 15h
- TomorrowUSDEIA Crude Oil Stocks Change●●●in 15h
- November 5, 2026USDInitial Jobless Claims●●●in 1 day
- November 6, 2026USDAverage Hourly Earnings m/m●●●Forecast 0.2%Previous 0.1%in 2 days
- November 6, 2026USDNonfarm Payrolls●●●Forecast 55KPrevious 29Kin 2 days
- November 6, 2026USDUnemployment Rate●●●Forecast 4.2%Previous 4.2%in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
What is being reported about DGX
📝 Overview Generated automatically?
DGX has been the subject of 3 signals across 3 articles in the last 365 days. Sentiment skews Bullish (67%).
Breakdown: 2 bullish, 0 bearish, 1 neutral. AI confidence averages 64% across all signals.
Most-cited catalysts: Strong organic revenue growth during the third quarter (1×), Upward revision of full-year 2026 revenue and EPS guidance (1×). Most-cited risk factors: Potential failure to sustain organic growth momentum (1×), Macroeconomic pressures impacting healthcare spending (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.